Overview

Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis

Status:
Withdrawn
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
An open-label,prospective, randomized pilot study to evaluate the efficacy, safety and tolerability of paeoniflorin, for the treatment of autoimmune hepatitis (AIH) with mild necroinflammatory activity on liver biopsy.
Phase:
Phase 3
Details
Lead Sponsor:
Xiaoli Fan
Treatments:
Peoniflorin
Silymarin